Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing-based measurement of fusion-transcript for MRD monitoring in CBF AML

ABSTRACT: RNA sequencing-based measurement of fusion-transcript for minimal residual disease (MRD) monitoring in core-binding factor acute myeloid leukemia (CBF AML)

PROVIDER: PRJEB27973 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR2717000.fastq.gz	Fastqsanger.gz
	ERR2717000_1.fastq.gz	Fastqsanger.gz
	ERR2717000_2.fastq.gz	Fastqsanger.gz
	ERR2717010.fastq.gz	Fastqsanger.gz
	ERR2717010_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 270

Similar Datasets

MRD Screening Of Human B ALL

Project description:MRD screening in Human B-ALL: monitoring B-cell repertoires in longitudinal samples of patients.

2015-09-04 | E-ERAD-391 | biostudies-arrayexpress

Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia

Project description:Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML). However, MRD cannot be detected in many patients using current methods. We developed a highly sensitive 5-hydroxymethylcytosine (5hmC) signature in cell-free DNA by analyzing 115 AML patients and 86 controls. The 5hmC method detected MRD in 20 of 29 patients with negative MRD by multiparameter flow cytometry and 11 of 14 patients with negative MRD by molecular methods. MRD detection by the 5hmC method was significantly associated with relapse-free survival. This novel method can be used in most AML patients and may significantly impact AML patient management.

2023-12-31 | GSE237057 | GEO

A real-world clinical genomic data platform for patients with colorectal cancer MRD detection: a retrospective-prospective study

Project description:Interventions: Case series:None Primary outcome(s): Minimal residual focus;recurrence rate, RR;recurrence-free surval, RFS;MRD recurrence lead time, MRD-RLT Study Design: Sequential

| 88263 | ecrin-mdr-crc

Measuring Minimal Residual Disease beyond 10-5 through IGHV leader-based NGS increases Prognostic Discrimination in Chronic Lymphocytic Leukemia

Project description:The sensitivity of conventional techniques for the quantification of minimal/measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) is limited to MRD 10-4. Measuring MRD <10-4 could help to further distinguish between CLL patients with durable remission and those at risk of early relapse. We here present a novel, academically developed IGHV leader-based next-generation sequencing (NGS) assay for the quantification of MRD in CLL. We demonstrate, based on measurements in contrived MRD samples, that the linear range of detection and quantification of our novel assay reaches beyond MRD 10-5. If provided with sufficient DNA input, MRD can even be detected down to MRD 10-6. There was high inter-assay concordance between measurements of the IGHV leader-based NGS assay and allele-specific oligonucleotide quantitative PCR (r=0.92, [95%CI 0.86-0.96]) and droplet digital PCR (r=0.93, [95%CI 0.88-0.96]) on contrived MRD samples. In a cohort of 37 patients from the CLL11 trial, using MRD 10-5 as a cut-off, MRD undetectability was associated with superior progression-free survival (PFS) and time to next treatment. Importantly, deeper MRD measurement allowed for additional stratification of patients with MRD <10-4 but ≥10‑5. Whereas the PFS of these patients was significantly shorter, compared to patients with MRD <10-5 (HR 4.9, [95%CI 1.3-17.9], P=0.017), their PFS was superior to those with MRD ≥10‑4 (HR 0.18, [95%CI 0.06-0.46], P<0.001). These results clearly demonstrate the clinical utility of the novel IGHV-leader based NGS assay.

2021-11-13 | GSE188587 | GEO

Search for New Biomarkers for the Monitoring of the Minimal Residual Disease of the Acute Lymphoblastic Leukemia.

Project description:The main goal of the research was to find some new biomarkers for the monitoring of the Minimal Residual Disease in Acute Lymphoblastic Leukemia patients. Keywords: Search for new Biomarkers

2008-03-15 | GSE10820 | GEO

Protein turnover measurement using selected reaction monitoring-mass spectrometry (SRM-MS) C4PR_LIV

Project description:Protein turnover represents an important mechanism in the functioning of cells, with deregulated synthesis and degradation of proteins implicated in many diseased states. Therefore, proteomics strategies to measure, with high confidence, turnover rates are of vital importance to understanding many biological processes. In this study, the more widely used approach of non-targeted precursor ion signal intensity (MS1) quantification is compared to selected reaction monitoring (SRM), a data acquisition strategy that records data for specific peptides, to determine if improved quantitative data would be obtained using a targeted quantification approach. Using mouse liver as a model system, turnover measurement of four tricarboxylic acid cycle proteins was performed using both MS1 and SRM quantification strategies. SRM outperformed MS1 in terms of sensitivity and selectivity of measurement, allowing more confident determination of protein turnover rates. SRM data is acquired using cheaper and more widely available tandem quadrupole mass spectrometers, making the approach accessible to a larger number of researchers than MS1 quantification, which is best performed on high mass resolution instruments. SRM acquisition is ideally suited to focussed studies where the turnover of tens of proteins is measured, making it applicable in determining the dynamics of proteins complexes and complete metabolic pathways.

2016-08-10 | PXD004413 | Pride

Enhanced detection of MRD with cfDNA Fragmentomics.

Project description:The circulating tumor DNA (ctDNA) mutation-based approach shows limited performance in minimal residual disease (MRD) detection, especially for landmark MRD detection at an early-stage cancer after surgery. Here, we describe a cell-free DNA (cfDNA) fragmentomics-based method in MRD detection of resectable non-small cell lung cancer using whole genome sequencing, and the cfDNA-fragmentomics showed a great sensitivity in predicting prognosis.

| EGAS00001007192 | EGA

CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD

Project description:Patients with stage Ⅰ colorectal cancer or stage Ⅱ colon cancer usually have a good prognosis and are not recommended to receive adjuvant chemotherapy after radical surgery. With the advances in liquid biopsy technology, detection of circulating tumor DNA (ctDNA) can effectively identify early-stage cancer patients with minimal residual disease (MRD) after surgery. According to the growing number of MRD studies in solid tumor, colorectal cancer patients with ctDNA-MRD detection have a poor clinical outcome and are likely to relapse within two years. This study aims to assess the efficacy of adjuvant chemotherapy with capecitabine plus oxaliplatin (CAPEOX) compared with conventional observation in MRD-positive patients with stage I colorectal cancer and clinically low-risk stage II colon cancer.

| 6161 | ecrin-mdr-crc

Nanostring based analysis of CBF-AML patients

Project description:miR-130a is captured as part of a 798 gene probe set on a microarray plate for 48 CBF patients In the group of patients defined here, survival characteristics and relapse information was collected to unbiasedly assess the impact of any miRNA on survival

2022-03-08 | GSE196177 | GEO

A microenvironment-inspired synthetic 3D model for pancreatic ductal adenocarcinoma organoids - 3D PEG-CBF-0.5 MS

Project description:LC-MS/MS based analysis of murine PCOs growing in 3D PEG-CBF-0.5 hydrogels for four days.

2021-11-29 | PXD022520 | Pride